Tranexamic Acid Use in Hemodialysis Patients

Critical Pharmacokinetic Concerns

Approximately 90% of Tranexamic Acid (TXA) is excreted unchanged in urine within 24 hours in patients with normal renal function, creating several compounding risks in hemodialysis patients due to impaired renal clearance 1, 2
Renal clearance is the major mechanism of TXA excretion, and impaired clearance correlates with increased incidence of neurotoxicity and ocular toxicity 1, 3

The American College of Cardiology and other guideline societies warn that TXA is an antifibrinolytic agent that may increase the risk of thromboembolic events, with venous and arterial thrombosis reported in treated patients, particularly relevant in hemodialysis patients who already face elevated baseline thrombotic risk 4, 5
The European Association for the Study of the Liver recommends against routine TXA use for procedural bleeding even in cirrhotic patients due to thrombotic concerns, and this caution applies even more strongly to dialysis patients with impaired clearance 6, 2

For patients on hemodialysis, the most conservative dosing should be employed, with a maximum safe dose of 10 mg/kg every 48 hours to minimize seizure and thromboembolic complications 3, 6

There is limited evidence supporting TXA use for specific indications, such as upper GI bleeding, in dialysis patients, with a pilot study showing that TXA significantly reduced early rebleeding and transfusion requirements, but used severely reduced dosing compared to standard protocols 4, 5

When considering TXA in hemodialysis patients, assess absolute contraindications, evaluate bleeding severity, use reduced dosing, monitor closely for signs of thrombosis and seizures, and discontinue as soon as bleeding is controlled 3, 6
The European Association for the Study of the Liver and other guideline societies recommend watching for dialysis access thrombosis, a particularly relevant thrombotic complication in this population that could result in loss of vascular access 6, 2